1. IL-32 production from lung adenocarcinoma cells is potentially involved in immunosuppressive microenvironment.
- Author
-
Zhao S, Li L, Komohara Y, Matsubara E, Shinchi Y, Adawy A, Yano H, Pan C, Fujiwara Y, Ikeda K, Suzu S, Hibi T, and Suzuki M
- Subjects
- Humans, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Macrophages immunology, Macrophages metabolism, Interferon-gamma metabolism, Interferon-gamma genetics, Interferon-gamma immunology, Immunohistochemistry, Male, A549 Cells, Tumor Microenvironment immunology, Interleukins metabolism, Interleukins genetics, Adenocarcinoma of Lung immunology, Adenocarcinoma of Lung pathology, Adenocarcinoma of Lung genetics, Adenocarcinoma of Lung metabolism, Lung Neoplasms immunology, Lung Neoplasms pathology, Lung Neoplasms genetics, Lung Neoplasms metabolism
- Abstract
Interleukin 32 (IL-32) is a proinflammatory cytokine secreted from several kinds of cancer cells. In the present study, we investigated the significance of IL-32 in lung adenocarcinoma by immunohistochemistry and bioinformatics analysis. IL-32 was positive in cancer cells of 21 cases (9.2%) of total 228 cases. Increased IL-32 gene expression was linked to worse clinical course in TCGA analysis, however, IL-32 expression in immunohistochemistry was not associated to clinical course in our cohort. It was also found that high IL-32 expression was seen in cases with increased lymphocyte infiltration. In vitro studies indicated that IFN-γ induced gene expression of IL-32 and PD1-ligands in lung adenocarcinoma cell lines. IL-32, especially IL-32β, also induced overexpression of PD1-ligands in human monocyte-derived macrophages. Additionally, Cancer-cell-derived IL-32 was elevated by stimulation with anticancer agents. In conclusion, IL-32 potentially induced by inflammatory conditions and anticancer therapy and contribute to immune escape of cancer cells via development the immunosuppressive microenvironment. IL-32 might be a target molecule for anti-cancer therapy., (© 2024. The Author(s) under exclusive licence to The Japanese Society for Clinical Molecular Morphology.)
- Published
- 2024
- Full Text
- View/download PDF